## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE PATENT EXAMINING OPERATION

First Named Inventor: BANDI PARTHASARADHI REDDY

Serial No: 10/509,139 Group Art Unit: 1625

Filed: 09-27-2004 Examiner: CHANG, CELIA C

Att. Docket No.: H1089/20010 Confirmation No.: 1949

For: NOVEL CRYSTALLINE FORMS OF (S)-CITALOPRAM OXALATE

## REQUEST FOR CONTINUED EXAMINATION AND AMENDMENT

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INTRODUCTORY COMMENTS

In response to the Office Action dated 05/07/2009, the time for responding thereto being extended in accordance with a Petition for Extension of Time submitted herewith, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.

A Request for Continued Examination is filed herewith.

CERTIFICATE OF MAILING/TRANSMISSION PURSUANT TO 37 CFR 1.8  I hereby certify that this correspondence and any attachments referenced therein is/are being-mailed/transmitted to the USPTO by; (A) first class U.S. mail with sufficient postage (37 CFR § 1.16)\(\frac{1}{2}\)\(\frac{1}\2\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac{1}{2}\)\(\frac	
1.6 (d)); or (C) EFS-Web (37 CFR § 1.6(a)(4)) on the date shown below.	
Date: _8/25/2009 Signature:	h
Name:	Joseph F. Murphy